Spiro-lactam NMDA receptor modulators and uses thereof
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
1. A method of treating neuropathic pain associated with fibromyalgia, in a patient in need thereof, the method comprising administering to the patient a pharmaceutically effective amount of a compound having the formula:
or a stereoisomer and/or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the compound has the formula:
or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the compound has the formula:
or a pharmaceutically acceptable salt thereof.
4. A method of treating fibromyalgia, in a patient in need thereof, the method comprising administering to the patient a pharmaceutically effective amount of a compound having the formula:
or a stereoisomer and/or a pharmaceutically acceptable salt thereof.
5. The method of claim 4 , wherein the compound has the formula:
or a pharmaceutically acceptable salt thereof.
6. The method of claim 4 , wherein the compound has the formula:
or a pharmaceutically acceptable salt thereof.
7. A method of treating neuropathic pain associated with diabetic neuropathy, in a patient in need thereof, the method comprising administering to the patient a pharmaceutically effective amount of a compound having the formula:
or a stereoisomer and/or a pharmaceutically acceptable salt thereof.
8. The method of claim 7 , wherein the compound has the formula:
or a pharmaceutically acceptable salt thereof.
9. The method of claim 7 , wherein the compound has the formula:
or a pharmaceutically acceptable salt thereof.